Prasugrel Tablet, Film Coated
Product Images NDC 60505-4642

10 FDA label images from Apotex Corp. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 60505-4642). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 01)

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 01)
A line graph comparing the percentage of non-CABG-related TIMI major or minor bleeding events over days from randomization between patients taking Prasugrel tablets and Clopidogrel. The y-axis shows the percentage of bleeding events, and the x-axis shows days from randomization up to 450 days. The graph includes a smaller inset chart showing an expanded view of the first 7 days. Numbers at risk for both groups are listed below the graph at various time points.*
FDA Label Image

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 02)

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 02)
Chemical structure of prasugrel hydrochloride depicted as a molecular diagram showing bonds, rings, and atoms corresponding to its complex formula.*
FDA Label Image

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 03)

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 03)
A line graph showing the inhibition of platelet aggregation (%) over time (hours), with mean and standard deviation plotted for 20 µM ADP. The graph depicts rapid increase in inhibition within the first few hours, then stabilizing around 75-80% inhibition up to 24 hours.*
FDA Label Image

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 04)

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 04)
A line graph comparing cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke percentages over days from randomization between prasugrel tablets and clopidogrel in UA/NSTEMI patients. The graph shows prasugrel tablets with lower event rates over time, with p-values indicated for statistical comparison.*
FDA Label Image

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 05)

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 05)
A line graph presenting cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (%) over days from randomization for Prasugrel Tablets versus Clopidogrel in STEMI patients. The graph shows two curves comparing the event rates over 450 days, with a significant p-value of 0.02. An inset zooms in on the initial 7 days, highlighting early differences with p=0.008.*
FDA Label Image

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 06)

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 06)
A forest plot comparing percent events and hazard ratios between Prasugrel Tablets and Clopidogrel across various baseline characteristics and subgroups. The chart includes categories such as age, gender, body weight, region, diabetes mellitus status, metabolic syndrome, previous medical conditions, time from symptom onset, stent type, and GP IIb/IIIa inhibitor use. Each subgroup shows event rates and hazard ratios with confidence intervals.*
FDA Label Image

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 07)

Image (Af9859ae Ee11 4d3e 8471 5bebfd473c21 07)
A forest plot chart comparing the hazard ratios of clinical events between Prasugrel tablets and Clopidogrel in various patient subgroups, including age, gender, body weight, geographic region, diabetes status, metabolic syndrome, previous cardiovascular events, time from symptom onset, stent type, and use of GP IIb/IIIa inhibitors. The chart visually represents which drug performs better across these categories.*
FDA Label Image

Prasugrel Tablets Usp 5 mg (Af9859ae Ee11 4d3e 8471 5bebfd473c21 08)

Prasugrel Tablets Usp 5 mg (Af9859ae Ee11 4d3e 8471 5bebfd473c21 08)
Label for Prasugrel Tablets, USP 5 mg oral film-coated tablets, manufactured by Panacea Biotec Pharma Limited and labeled for Apotex Corp. The label indicates a bottle with 30 tablets, with instructions to keep in the original container and dispense the medication guide. The NDC number 60505-4642-3 is shown. The label includes storage instructions and a small image of a round tablet imprinted with '5'.*
FDA Label Image

Prasugrel Tablets Usp 10 mg (Af9859ae Ee11 4d3e 8471 5bebfd473c21 09)

Prasugrel Tablets Usp 10 mg (Af9859ae Ee11 4d3e 8471 5bebfd473c21 09)
Label for Prasugrel Tablets USP 10 mg oral film-coated tablets. The label states a package size of 30 tablets and that the product is manufactured for Apotex Corp. It includes usage instructions, storage conditions, and a depiction of a round, orange tablet imprinted with '10'. The label also mentions the product is prescription only and manufactured by Panacea Biotec Pharma Limited in India.*
FDA Label Image

Prasugrel Tablets Usp 10 mg (Af9859ae Ee11 4d3e 8471 5bebfd473c21 10)

Prasugrel Tablets Usp 10 mg (Af9859ae Ee11 4d3e 8471 5bebfd473c21 10)
This label for Prasugrel Tablets, USP shows the 10 mg film-coated oral tablet strength in a 30-tablet package. The label includes the NDC code 60505-4856-3, manufacturer Apotex Corp., and mentions the tablets contain prasugrel hydrochloride equivalent to 10 mg prasugrel. Storage instructions, barcode, and a tablet image embossed with '10' are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.